Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
about
Crizotinib: A comprehensive reviewClinical use of crizotinib for the treatment of non-small cell lung cancerThe biology and treatment of EML4-ALK non-small cell lung cancerCrizotinib resistance: implications for therapeutic strategiesNon-small cell lung cancer: current treatment and future advancesMolecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugsMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularSecond-Line Therapy for Advanced NSCLCReview of the current targeted therapies for non-small-cell lung cancerCIViC databaseMolecular pathology of lung cancer: key to personalized medicine.Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domainAnaplastic lymphoma kinase inhibition in non-small-cell lung cancer.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisALK mutations conferring differential resistance to structurally diverse ALK inhibitors.ROS1 rearrangements define a unique molecular class of lung cancers.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceSecond- and third-generation ALK inhibitors for non-small cell lung cancerPersonalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinibThe Structural Characterization of Tumor Fusion Genes and ProteinsClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKMutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis.A mouse model for EML4-ALK-positive lung cancernab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expressionDetecting ALK, ROS1 and RET Fusion Genes in Cell Block SamplesMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularKLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue onlyCurrent concepts on the molecular pathology of non-small cell lung carcinoma.Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.Chromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer
P2860
Q24624083-01155A97-78A4-4E09-805B-B431C8A49E5CQ24630466-0CA098EE-386F-42B2-A22A-A2EF98EA41F2Q24632625-5987136B-166B-4C19-B9D5-82A0AABD2AC7Q26738381-2D52920D-F3E2-462D-AD6C-B6C4F2DC5219Q26740333-EF0417D5-CD6C-4EF0-AB77-E037FA45DDA8Q26769659-3DC7E65A-E3C4-42B4-B2CA-E180D370A76DQ26771116-939A415D-833A-4F06-BDF0-8656F3DBDCB0Q26820845-86B9DBB0-35F1-4D52-93BA-437B13E3DB51Q26828860-3D5E9434-1E5F-4EBC-AD9B-48F38B5BAE02Q27002398-F66CCFCF-730D-4D15-88D2-24688F09BA21Q27015079-B7ECB702-C379-417D-B088-071B1AB0C4FBQ27612411-EE998059-15E6-4C36-8E5E-B51BAC52F74FQ27691299-20E5BE95-B502-48D3-8791-A71C30A7F312Q27698105-0AA7F7D7-5A34-42B8-A92F-6F12E542D994Q27851588-57794EF1-5730-4E75-A102-602FC120E038Q27851671-F01A7EA9-1ED8-464A-AB24-FCA307991567Q27851672-64446EAF-B1CF-4212-95C5-F786A2DBF001Q27851700-73ABDEDB-6070-4934-AD8D-0AC1E1D2052BQ27851702-816A9F29-7B60-4DD0-9E76-9D16A1FF74AFQ27851704-9B8D8602-1B2E-4DAA-90F4-3792667D55F3Q27852699-0BAC64CD-AA6A-4F29-8E39-F41D70E3998FQ28071903-C79F58EE-813E-4E1D-A944-1B916C70A0EBQ28072496-7062E649-55C9-46E4-8C95-B3D6AE25F278Q28083711-8CD8A745-640B-4C8F-940D-8623FAD1570FQ28386511-7237DA88-2767-4BCC-8784-4DEA69F7CD6CQ29615472-E045B2E1-4ECE-440D-9C1D-0FD849E132C8Q30372506-73BE7C49-F1C1-4154-B87B-52C0AB1D0F08Q30485093-A9A83EAC-8BAE-4C6E-B224-C2B3BC1F87A9Q33412928-DBD804F0-610B-4813-A2C4-CE4E54128F22Q33699169-EF01319F-8E9D-45B1-AB4A-FBB90A757296Q33844713-72D94796-52E1-4D15-A7F5-6F64D2A65B0BQ34013976-BD29E263-A28F-4A04-B711-79F005B6A0A9Q34092187-9B452D58-C244-4F45-BFC5-C7497DDB6B66Q34159011-CF329322-7D14-4484-BB15-E250F58503C5Q34162787-A0589D39-4687-4076-8E38-15BB9BE8803BQ34310062-8F9AF456-EE37-48E0-9E0D-985A225A01C4Q34349164-7AD4E80F-77F5-404F-9C26-1296026A4CDDQ34389047-44717BB2-3430-441D-A152-9C9CFEE0F1F3Q34536679-B4E0BA39-6FF2-4BA9-9D55-B09D8A222260Q34558207-BB8422CC-C63F-4C9C-A7A0-1AE505C4B39B
P2860
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@ast
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@en
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@nl
type
label
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@ast
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@en
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@nl
prefLabel
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@ast
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@en
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
@nl
P2093
P3181
P1476
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
@en
P2093
Hiroyuki Mano
Ken Nakagawa
Manabu Soda
Munehiro Enomoto
Sakae Okumura
Satoko Hatano
Shuji Takada
Yoshihiro Yamashita
Young Lim Choi
Yuichi Ishikawa
P304
P3181
P356
10.1158/1078-0432.CCR-08-1018
P407
P577
2008-10-01T00:00:00Z